companiesandmarkets.com

Summary: Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn′s disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.

Scope

Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists′ prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure

Highlights

Clinical guidelines recommend a step-up treatment approach. However, this survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and this approach will become more commonplace in the future.

Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but this survey suggests currently only 30% of these patients go on to receive Humira.

Shire′s Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.

Reasons to Purchase

Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies

Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.

www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.